Treatment‐related adverse events of antibody–drug conjugates in clinical trials: A systematic review and meta‐analysis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Treatment‐related adverse events of antibody–drug conjugates in clinical trials: A systematic review and meta‐analysis
Authors
Keywords
-
Journal
CANCER
Volume 129, Issue 2, Pages 283-295
Publisher
Wiley
Online
2022-11-21
DOI
10.1002/cncr.34507
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
- (2021) Paolo Tarantino et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Antibody–Drug Conjugates for Cancer Therapy
- (2020) Umbreen Hafeez et al. MOLECULES
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia
- (2018) Jeffrey Baron et al. Expert Review of Clinical Pharmacology
- A Brief Introduction to Antibody–Drug Conjugates for Toxicologic Pathologists
- (2018) Lars Mecklenburg TOXICOLOGIC PATHOLOGY
- Strategies and challenges for the next generation of antibody–drug conjugates
- (2017) Alain Beck et al. NATURE REVIEWS DRUG DISCOVERY
- Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
- (2016) Heather Donaghy mAbs
- Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma
- (2016) David A. Reardon et al. NEURO-ONCOLOGY
- Antibody–drug conjugates—A new wave of cancer drugs
- (2014) Hervé Bouchard et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Ocular Toxicity of Targeted Therapies
- (2012) Daniel J. Renouf et al. JOURNAL OF CLINICAL ONCOLOGY
- ERBB2 Inhibition and Heart Failure
- (2012) Gregory M. Cote et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
- (2010) Anjali Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started